<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3045">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04773067</url>
  </required_header>
  <id_info>
    <org_study_id>V-205</org_study_id>
    <nct_id>NCT04773067</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult Volunteers</brief_title>
  <official_title>A Phase II, Placebo-controlled, Randomized, Observer-blind Study to Evaluate the Immunogenicity, Safety, and Tolerability of UB-612 Vaccine Against COVID-19 in Adolescent, Younger and Elderly Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United Biomedical Inc., Asia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>COVAXX</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>United Biomedical Inc., Asia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, observer-blind, multiple-centre, randomized, placebo-controlled study to&#xD;
      evaluate the immunogenicity, safety, tolerability and lot consistency of 2 doses of UB-612&#xD;
      vaccine in adolescent, younger and elderly adults.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric mean titer (GMT) of SARS-CoV-2 neutralizaing antibody</measure>
    <time_frame>Day 57</time_frame>
    <description>Evaluation of immunogenicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion rate (SCR) of SARS-CoV-2 neutralizing antibody</measure>
    <time_frame>Day 57</time_frame>
    <description>Evaluation of immunogenicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety evaluation</measure>
    <time_frame>Day 1 to Day 197</time_frame>
    <description>Local reactions and systemic events for up to 7 days following each dose&#xD;
Unsolicited adverse events from Day 1 to Day 57&#xD;
MAAEs, SAEs, AESIs and ADEs from Day 1 to Day 197</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SCR of anti-S1-RBD antibody</measure>
    <time_frame>Day 57</time_frame>
    <description>Evaluation of immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of SARS-CoV-2 neutralizing antibody</measure>
    <time_frame>Day 197 and 365</time_frame>
    <description>Evaluation of immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of anti-S1-RBD antibody</measure>
    <time_frame>Day 57, 197 and 365</time_frame>
    <description>Evaluation of immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean fold increase in anti-S1-RBD and SARS-CoV-2 neutralizing antibodies</measure>
    <time_frame>Day 57, 197 and 365</time_frame>
    <description>Evaluation of immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of lot to lot consistency</measure>
    <time_frame>Day 57</time_frame>
    <description>As assessed by the comparisons of the GMT of SARS-CoV-2 neutralizing antibody induced by 3 independent clinical materials</description>
  </secondary_outcome>
  <other_outcome>
    <measure>GMT of SARS-CoV-2 neutralizing antibody in adolescents</measure>
    <time_frame>Day 57</time_frame>
    <description>Evaluation of immunogenicity</description>
  </other_outcome>
  <other_outcome>
    <measure>SCR of SARS-CoV-2 neutralizing antibody in adolescents</measure>
    <time_frame>Day 57</time_frame>
    <description>Evaluation of immunogenicity</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety evaluation in adolescents</measure>
    <time_frame>Day 1 to Day 365</time_frame>
    <description>Local reactions and systemic events for up to 7 days following each dose&#xD;
Unsolicited AEs from Day 1 to Day 57&#xD;
MAAEs, SAEs, AESIs and ADEs from Day 1 to Day 365</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of COVID-19 cases</measure>
    <time_frame>Day 1 to Day 365</time_frame>
    <description>COVID-19 incidence per 1000 person-years of follow-up</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3850</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>UB-612</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A proprietary high-precision designer S1-RBD-protein based vaccine incorporating a Th/CTL epitope peptide pool which could bind to human MHC-I and MHC-II to activate T cells.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% sodium chloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UB-612</intervention_name>
    <description>Around 3850 adult subjects will be enrolled into core group, and 385 adolescents will be recruited for supplementary group.</description>
    <arm_group_label>UB-612</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Around 3850 adult subjects will be enrolled into core group, and 385 adolescents will be recruited for supplementary group.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or non-pregnant female between the age of 12 to 85 years at time of&#xD;
             enrolment.&#xD;
&#xD;
          -  Women of childbearing potential and men must agree to practice medically effective&#xD;
             contraception from first vaccination until 3 months after the last vaccination.&#xD;
&#xD;
          -  Able to understand the content and possible risks of informed consent and willing to&#xD;
             sign the Informed Consent Form (ICF).&#xD;
&#xD;
          -  Able to understand and agrees to comply with all study procedures and be available for&#xD;
             all study visits.&#xD;
&#xD;
          -  Ear temperature ≤ 38.0°C.&#xD;
&#xD;
          -  Healthy participants who are determined by medical history, physical examination, and&#xD;
             clinical judgment of the investigator to be eligible for inclusion in the study. In&#xD;
             the investigator's clinical judgement, participant may have a stable and&#xD;
             well-controlled comorbidity associated with an increased risk of progression to severe&#xD;
             COVID-19.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of anaphylaxis, urticarial, or other significant adverse reaction requiring&#xD;
             medical intervention after receipt of a vaccine.&#xD;
&#xD;
          -  Female who is pregnant or positive in pregnancy test at screening or just prior to&#xD;
             each vaccination administration.&#xD;
&#xD;
          -  Female who is breast-feeding or plans to breastfeed from the time of the first&#xD;
             vaccination through 60 days after the last vaccination.&#xD;
&#xD;
          -  Any acute illness, as determined by the study investigator 3 days before first&#xD;
             vaccination (these subjects can be re-scheduled).&#xD;
&#xD;
          -  Any major surgery one month before first vaccination (these subjects can be&#xD;
             -rescheduled).&#xD;
&#xD;
          -  Known HIV antibody positive.&#xD;
&#xD;
          -  Known active hepatitis B and hepatitis C disease.&#xD;
&#xD;
          -  Previous exposure to SARS-CoV-2 or receipt of an investigational or licensed product&#xD;
             for the prevention of COVID-19, MERS or SARS.&#xD;
&#xD;
          -  Have history of Guillain-Barre syndrome.&#xD;
&#xD;
          -  Subjects who take part in another clinical study within 12 weeks prior to the day of&#xD;
             informed consent.&#xD;
&#xD;
          -  Immune deficiency/disorder, whether due to genetic defect, immunodeficiency disease or&#xD;
             immunosuppressive therapy.&#xD;
&#xD;
          -  Subjects who plan to or are undergoing anti-cancer therapy.&#xD;
&#xD;
          -  Platelet disorder or other bleeding disorder may cause injection contraindication.&#xD;
&#xD;
          -  Prior chronic administration of immunosuppressant or corticosteroids, cytotoxic&#xD;
             treatment in last 6 months before first vaccination.&#xD;
&#xD;
          -  Prior administration of immunoglobulins and/or any blood products in last 4 months&#xD;
             before first vaccination.&#xD;
&#xD;
          -  Receipt of any seasonal or pandemic influenza vaccine within 14 days, or any other&#xD;
             non-study vaccine within 28 days, before study intervention administration.&#xD;
&#xD;
          -  Anticipated receipt of any seasonal or pandemic influenza vaccine within 14 days, or&#xD;
             any other nonstudy vaccine within 28 days, after study intervention administration.&#xD;
&#xD;
          -  Receipt of short-term (&lt;14 days) systemic corticosteroids. Study intervention&#xD;
             administration should be delayed until systemic corticosteroid use has been&#xD;
             discontinued for at least 28 days. Inhaled/nebulized, intra-articular, intrabursal, or&#xD;
             topical (skin or eyes) corticosteroids are permitted.&#xD;
&#xD;
          -  Loss or donation of blood over 500 mL within 3 months prior to Screening Visit or&#xD;
             intention to donate blood or blood products for transfusion during the study.&#xD;
&#xD;
          -  Any medical disease or condition that, in the opinion of the study investigator, may&#xD;
             confound the results of the study or pose an additional risk to the subjects by their&#xD;
             participation in the study.&#xD;
&#xD;
          -  Employees at the investigator's site, of the Sponsor or the contract research&#xD;
             organization (CRO) directly involved in the conduct of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chang-Yi Wang, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>United Biomedical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hope Liu, Ph.D.</last_name>
    <phone>+886-3-657-8861</phone>
    <phone_ext>5837</phone_ext>
    <email>hope.liu@ubiasia.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chun-Eng Liu, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Chun-Eng Liu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang-Geng Medical Foundation Kaoshiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chen-Hsiang Lee, M.D.,M.S.</last_name>
    </contact>
    <investigator>
      <last_name>Chen-Hsiang Lee, M.D.,M.S.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Po-Liang Lu, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Po-Liang Lu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hung-Chin Tsai, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Hung-Chin Tsai, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Far Eastern Memorial Hospital</name>
      <address>
        <city>New Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chun-Hsing Liao, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Chun-Hsing Liao, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kao-Pin Hwang, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Kao-Pin Hwang, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yi-Ching Yang, M.D., M.P.H.</last_name>
    </contact>
    <investigator>
      <last_name>Yi-Ching Yang, M.D., M.P.H.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuam-Jang Lee, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Yuam-Jang Lee, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fu-Der Wang, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Fu-Der Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Feng-Yee Chang, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Feng-Yee Chang, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang-Geng Medical Foundation Linkou Chang-Geng Memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ching-Tai Huang, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Ching-Tai Huang, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 23, 2021</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2021</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

